A high-throughput anti-aging drug screen was developed that simultaneously measures senescence-associated β-galactosidase activity and proliferation. Applied to replicatively pre-aged fibroblasts, this screen yielded violuric acid (VA) and 1-naphthoquinone-2-monoxime (N2N1) as its top two hits. These lead compounds extended the replicative life spans of normal and progeroid human cells in a dose-dependent manner and also extended the chronological life spans of mice and C. elegans. They are further shown here to function as redox catalysts in oxidations of NAD(P)H. They thus slow age-related declines in NAD(P)+/NAD(P)H ratios. VA participates in non-enzymatic electron transfers from NAD(P)H to oxidized glutathione or peroxides. N2N1 transfers electrons from NAD(P)H to cytochrome c or CoQ10 via NAD(P)H dehydrogenase (quinone) 1 (NQO1). Our results indicate that pharmacologic manipulation of NQO1 activity via redox catalysts may reveal mechanisms of senescence and aging.
Aging and senescence are accompanied by systemic changes in the structural integrity of cells that are caused by alterations in metabolic and signal transduction pathways.1 The proximal events which initiated the deterioration of complex cellular systems result in dramatic cell cycling deceleration and establishment of metabolically perplexed, irreversible non-dividing state. Indeed, early observations have indicated that normal cells are characterized by a limited replicative lifespan (RLS).2,3 The senesce associated β-galactosidase (SAβG) activity is considered one of the classic hall-marks of cell senescence.4 Among the others are telomere deterioration, multiple epigenetics changes in histones and DNA, metabolic perturbations caused by tendency of aging cells to rely more on glycolysis, hence, skewed mitochondrial dynamic toward more segregated, less respiring mitochondria.5 Senescence is also accompanied by increased expression of CDKN1A/2A (p21/p16) and a complex senescence-associated secretory phenotype.6
A small molecule high-throughput screen (HTS) requires proper selection of molecular markers for the robust and informative readout. Various approaches have been conceptualized for development of age-deceleration strategies,7 including, e.g., senolytics8 or senescence preventing strategies targeting various intracellular/extracellular pathways: telomerase machinery,9,10 DNA repair,11 nutrient response12 and, redox reaction.13 We focused on identification of agents that would prevent manifestation of classic senescence markers and overcome replicative block. We designed a new HTS for simultaneously measurement of ATP level that reflects the reenter into cell cycle and quantification of SAβG activity, an established marker of senesced cells.4 Our screen for anti-senescence agents generated a list of anti-aging compounds that were able to reactivate cell cycle progression in replicatively aged cells and at the same time down-regulate the SAβG activity. Direct RLS measurements in normal and progeroid human fibroblasts confirmed selection of the two most potent candidates. Detailed coverage of senescence molecular traits allowed to identify the molecular mechanisms of action of each lead compound. This work focusses on introductory characterization of anti-aging effects of violuric acid (VA) and 1-naphthoquinone-2-monoxime (N2N1) and aim to establish a potential utility of these compounds or their derivatives in prevention of cellular senescence or organismal aging.
Screen for anti-aging agents
The classic method for SAβG activity4 utilizes ferricyanide/ferrocyanide to amplify the X-gal development in formaldehyde fixed cells. The procedure requires up to 24 h and analysis with high content image examination by automated microscopy, which is time consuming and expensive. We developed a new technique (Fig. 1a) that requires considerably less time (1–2 h) to generate quantifiable signals with a very high signal-to-noise ratio. Our assay can be performed in any plate size (96-well or 384-well) that can be read by conventional plate reader. In short, β-galactosidase was released into a solution compatible with its enzymatic activity by adding Triton X100 and a catalyst, nitro blue tetrazolium salt (NBT), to shorten assay processing times. The buffer composition and formation of formazan precipitate did not interfere with ATP quantification using a standard luciferase-based approach. ATP could be detected without noticeable decay even 24 h after cell lysis and completion of SAβG activity measurements. The readout is SAβG activity (based on absorption at 615 nm) divided by normalized luciferase activity, which is proportional to ATP concentration. Such ratios were assessed relative to those of untreated control samples. Putative anti-aging drug candidates would decrease SAβG while leaving ATP unchanged or elevated; the former corresponds to normal slow-growing pre-senesced cells, the latter to growth stimulated, replicating cells. This screen thus filters outs cytotoxic compounds that decrease ATP. Compounds with lower SAβG/ATP ratios were thus considered to be better hits. We applied this approach to a small library of bioactive compounds that was augmented to include, based on our previous research, a few additional anti-aging candidates. Several compounds were selected. We focused on the top two, VA and N2N1 (Fig. 1b, c).
Biologic properties of VA and N2N1
To further evaluate the effect of compounds on senescence phenotype in a standard tissue culture-based assay (Fig. 1d) we used several cell culture models: normal human dermal fibroblasts (NHDF), stromal/mesenchymal cells, progeroid fibroblasts derived from patients with Werner or Bloom syndromes, and a set of cancer cell lines (Fig. S1). To increase the stringency of experiments for selection of anti-aging drug candidates, NHDF were pre-aged by culturing them for up to 40 population doublings (PD): both compounds prolonged RLS in a dose-dependent manner (Fig. 1e). VA activity occurred at concentrations of 30–100 μM with no toxicity (Fig. 2a). N2N1 was most effective at 1 μM and showed some cytotoxicity above 10 μM (Fig. 2a): 10–15 additional PD were achieved with 1 μM of N2N1. VA was less effective and added 8–10 PD (Fig. 1f, left plots). Compared to untreated controls capable of 45–50 PD, VA and N2N1 increased RLS by 15–30%; in the same system rapamycin (1 nM) increased RLS by only 5–10%.14 VA and N2N1 restored cell cycle progression rates to those of young cells and also restored fibroblast-like morphology and decreased SAβG. When we tested N2N1 and VA on progeroid cells (Fig. 1f, right plots) derived from subjects with Bloom (BLM) or Werner (WRN) syndrome, BLM (but not WRN) fibroblasts responded to N2N1 and VA with increased proliferative capacity. BLM fibroblasts responded to N2N1 and VA by acquiring five additional PD and by increasing RLS by ~50%. VA and N2N1 down-regulated p16, p21 and γH2A.X and upregulated lamin B1 (Fig. 1g). Examined by qPCR, VA, and N2N1 affected telomere maintenance in NHDF (Fig. S2d). The culture of stromal cells derived from normal bone marrow had long telomeres at the start and at the end of the experiment. Despite this telomere maintenance, these cells experienced a broader spectrum of replicative senescence features, including p16/p21 upregulation and thus withdrawal from cell cycle (data not shown) and hypertrophic morphology. No changes in mitochondrial respiration or glycolysis were detected in the presence of the compounds (Fig. S2a, b and c). In addition, a small panel of cancer cell lines was tested with lead compounds to test the effect of drugs on cancerous phenotype (Fig. S1). We could not detect any acceleration of cell cycle progression after treatment with N2N1 or VA, probably because cultured cancer cells are already at their maximum cycling speed.
While the main focus of this study is the effect of VA and N2N1 on RLS, we also performed a pilot experiment to evaluate the possible effect of the compounds on chronological life span (CLS) in two different animal models: mouse and C. elegans. We observed an elevated survival rate during normal aging if animals received N2N1 or VA (Fig. 1h), and both compounds extended the CLS of wild-type mice and worms. To further understand the effect of VA and N2N1 on CLS, a more detailed analysis will be required with multiple aging related mutations (daf-2, age-1, clk-1 etc.), caloric load and, oxidative stress or signaling taken into consideration.
N2N1 and VA are redox catalysts and could thus alter a wide range of biomolecules. To evaluate the cytotoxic, genotoxic, and oxidative potentials of N2N1 and VA, we performed a set of tests, results of which are shown in Fig. 2. Both compounds were tolerable, with N2N1 LD50 above 10 μM and VA LD50 above 1 mM (Fig. 2a), therefore exhibiting very broad therapeutic index beneficial for further translational research. The Ames assay and comet assay yielded that VA and N2N1 are not genotoxic (Fig. 2b, c). The Amplex red assay was used to evaluate reactive oxygen species (ROS) generation by N2N1 and VA (Fig. 2d), during direct electron transfer from NADH or electron transfer mediated by enzymes after addition to the reaction mix cytoplasmic extract prepared from NHDF (Fig. 2e). We could not detect any significant increase in resorufin fluorescence at any condition tested after treatment with VA. Addition of VA even slightly decreased the spontaneous generation of resorufin (Fig. 2d). N2N1 effect on ROS generation was vague and completely disappeared after addition of cytoplasmic extract to the reaction. While 10 μM of N2N1 increased resorufin formation slightly, this effect was quickly erased by the highly reductive capacity of cytoplasmic extract.
VA mechanism of action
We found that the only persistent effect of VA treatment was considerable reduction in global protein disulfide bonds (up to 30%) detected by Elman’s reagent or direct labelling of available sulfahydril groups with a biotin-switch assay (Fig. 3a). This observation was in line with the “reductive hypothesis of aging”.15 We tested the enzymatic activities of thioredoxin reductase, glutathione reductase, peroxiredoxins, G6PD, 6PG, IDH1/2, LDH, MDH1/2, PDH, and αKG complexes (Fig. 3b). Reaction rates of these enzymes did not change upon treatment with VA or N2N1 (data not shown, assays protocols are in suppl. Material and methods). We then queried the possible involvement of VA in sulfhydryl oxidation. Using control samples containing all components of reaction mix except cellular extract, we detected non-enzymatic oxidation of NAD(P)H (Fig. 3c, left plot and Fig. S3a, S4a). Thus, VA likely catalyzes the non-enzymatic transfer of electrons from NAD(P)H to O2. In confirmatory experiments, we tested whether NADH or NADPH is a better electron donor to VA and found NADH to be oxidized at a higher rate (Fig. 3 and Fig. S3 and S4). To confirm that VA is a good lead scaffold for the development of better redox catalysts, we also tested related diphenyl- and dimethyl-violuric acid (Ox12 and Ox13; Fig. S3, S4). Whereas the diphenyl group addition increased the oxidation rate of NAD(P)H, the dimethyl group addition did not. Next, we observed that addition of GssG or H2O2 to the reaction increases the reaction rate (Fig. 3c, middle and right plots and Table S3). Both NADH and NADPH can be utilized, but NADH was oxidized faster (Fig. S3 and S4). H2O2 and oxidized glutathione were reduced better by VA, or its dimethyl analog Ox13, than by its diphenyl analog Ox12. Treatment with VA (30 μM) considerably increased the ratio of reduced to oxidized glutathione (Fig. 3d and Fig. S6b). One hour of incubation with VA was enough to push the ratio up and an effect was still observed after one day and to lesser extent after 3 days of treatment (Fig. 3d). VA also moderately increased the NAD+/NADH ratio after one hour of treatment and the effect may last for additional 24 h (Fig. S6a). We also tested whether VA can be used for direct electron transfer from NAD(P)H to the disulfide bonds formed inside a protein or between the proteins using a turbidity assay with insulin, but no reduction of disulfide was seen (Fig. S5).
VA could participate in non-enzymatic reduction of cytochrome c by NADH (Fig. 3e). Addition of cytoplasmic extract (with rotenone and Tx100 to inhibit mitochondrial respiration) supplemented with NADH slightly changed the reaction rates, but did not change the overall picture (Fig. 3f). Most likely, VA does not support the enzymatic electron transfer from NADH to cytochrome c. Cytochrome c can also be used as a surrogate substrate for evaluation of NADPH dependent cytochrome P450 oxidoreductases. NADPH supplemented cytoplasmic extract prepared from aged NHDF could quickly reduce cytochrome c independent of VA dose applied (Fig. 3g).
In sum, our data demonstrate that observed VA anti-aging effects on multiple cell types may stem from non-enzymatic electron transfer from NAD(P)H to H2O2 or oxidized glutathione (Fig. 3h). Impacted processes, generation of NAD+, cell signaling based on ROS, and intracellular redox control of glutathione, are all pivotal to aging, senescence, and stem cell maintenance.
N2N1 mechanism of action
Previous studies reported the catalytic activities of N2N1 isomers in non-enzymatic and enzymatic systems by pyridine and flavin coenzymes.16 These catalytic activities occurred in the presence of molecular oxygen or cytochrome c and liver-derived microsomal extracts with NADH and NADPH serving as electron donors. We therefore investigated enzymes and substrates which could partner with N2N1 as redox catalysts (Fig. 4a). N2N1 accepting electrons from NAD(P)H was confirmed by a gradual decrease in absorption at 340 nm with the addition of cytosolic enzymes into the reaction mixture (Fig. 4b, Table S4). The rate of NAD(P)H oxidation by molecular oxygen was slow (Table S4), but increased with N2N1 (at 3–10 μM, Fig. 4b). Addition of alternative substrates increased the rate of non-enzymatic NAD(P)H oxidation, while cytochrome c retarded the reaction (Fig. 4d middle plot, Table S4). Therefore, N2N1 can accept electrons from NADH and NADPH, but it prefers NADH. We compared O2, cytochrome c and H2O2 as electron acceptors (Fig. 4c, Table S4) in enzyme-supported reactions with N2N1. The reaction rate increased with the addition of cytochrome c, but not H2O2.
To characterize the N2N1-dependent activity, we used a set of enzyme-specific inhibitors (Fig. 5 and Table S5) with different electrons donors: NADH or NADPH. Inhibitors of mitochondrial complexes I (rotenone), III (antimycin A) and IV (cyanide) did not affect N2N1-mediated cytochrome c reduction (Fig. 5a, lower plots). Hence, we excluded the mitochondrial respiration complexes as N2N1 targets. We then determined if cytochrome c reduction could be blocked by dicumarol or pHMB, i.e., potent inhibitors of the oxidoreductases NQO1 and CYB5R, respectively. Dicumarol inhibited the reaction and pHMB did not (Fig. 5a, upper plots). Similar results were observed in NADPH: cytochrome c electron transfer: dicumarol inhibited the N2N1 assisted reaction, while pHMB did not (Fig. 5b and Table S6). It should be noted that NADPH:N2N1:cytochrome c reaction inhibited by dicumarol was not complete and less pronounced than in tests with NADH as the electron source. This raises a possibility that N2N1 may also stimulate some CYP enzyme driven reactions.
To elaborate more on N2N1–NQO1 mechanism, we tested the reactivity of natural NQO1 substrate CoQ10 (Fig. 6a and Table S7a). N2N1 catalyzed electron transfer from NADH to CoQ10, an effect that was inhibited by dicumarol. We also tested if well-established partners of NQO1, β-lapachone and dunnione can ameliorate the replicative decay of senesced fibroblasts. Indeed, both compounds slowed down this process (Table 1). Cell populations with NQO1 knocked out by CRISPR/Cas9 did not respond to N2N1, β-lapachone or dunnione treatments (Table 2 and Fig. S7c). Taken together, this study unequivocally identified N2N1 as a molecule whose effects depend on NQO1 enzymatic activity (Fig. 6c).
After careful consideration of molecular markers of senescence in pre-aged cells, we decided to focus on SAβG activity and synchronous detection of ATP as a feature of cell cycle reentry. SAβG activity was measured after cell lysis in solution containing X-gal and NBT. NBT cycling substantially increases the rate of enzyme specific X-gal cleavage and thus the signal intensity. The reaction was compatible with simultaneous ATP detection via luciferase activity. This new technique was applied to normal pre-senesced human fibroblasts. It enabled selection of a lead set of small molecules with anti-aging properties.
The two most effective compounds were chosen after a secondary, confirmatory screen. They shared a molecular structure that allows them to effectively accept, carry, and donate electrons, i.e., they belong to families of redox catalysts that could potentially participate in multiple enzymatic reactions. VA is better known as a redox catalyst17 than N2N1.16 Molecules with similar structures are broadly used as redox mediators in many biochemical and medical applications,18 and some may contribute to the extension of RLS13,19 or CLS.20,21 Both N2N1 and VA extended RLS of NHDF and stromal cells isolated from normal bone marrow. The primary cell cultures used in our study, skin fibroblasts and especially bone marrow stromal cells, while morphologically uniform, contain a well-defined population of stem cells. For example, human skin contains a population of so-called skin-derived progenitors (SKPs).22 Bone marrow derived stromal culture is a very potent supplier of multipotent progenitor cells with diverse differentiation pathways.23 Therefore, it is possible that anti-aging drugs maintain the stem cell compartment by supporting stem cell self-renewal.
Bloom syndrome fibroblasts acquired additional replicative potential after treatment with VA or N2N1. In contrast, Werner syndrome cells were not responsive at all. Loss of BLM vs. WRN helicase may result in DNA damage repair systems that have different remaining dependencies on NAD+; NAD+ is the main substrate of poly (ADP-ribose) polymerase (PARP), which is known to be involved in alt-NHEJ, but not classical NHEJ, DNA DSB repair.
It has been reported that VA may act as an anti-oxidant24 or protect cells against chemically induced hypoxia.25 Based on our biochemical analysis we showed no influence (positive or negative) of VA on oxidative respiration, glycolysis, thioredoxin or glutathione, NADPH-generating dehydrogenases, or NADH-generating dehydrogenases (e.g., PDH or αKGDH). VA and its analogs did not modulate CYB5R and POR enzymatic activity, but VA did accept electrons from NAD(P)H and pass them along to other electron acceptors. In non-enzymatic reactions, hydrogen peroxide increased the reaction rate, indicating that VA is capable of reducing it further to water. VA was also able to donate its electrons to oxidized glutathione, thus recharging it to serve as an antioxidant. In this reaction, the rate jumped several times and that explained our original observation of elevated levels of reduced sulfhydryls after treatment of cells with VA for several days. Again, the effect of VA was quite specific for reduction of disulfide bonds in oxidized glutathione, because we could not see the reduction of disulfide bonds by VA in insulin as a substrate. Our results thus lead us to propose that VA mediates its anti-aging effect through very specific, direct reduction of oxidized glutathione and at lesser extent, reduction of peroxide. Therefore, VA and its analogs could be quite specific, with minimal side effects.
A similar approach was used to elucidate the anti-aging mechanism of N2N1. It should be emphasized that N2N1 and its isomer N1N2 exists in solution as oxime tautomers only26,27 and it has already been reported that molecules with a similar scaffold may have both anti-oxidant and anti-neoplastic properties.28 N2N1 at 1 μM increased the NAD+/NADH ratio after one hour of treatment and the effect became much more evident after additional 24 h (Fig. S6a). The increase in NAD+ level alone is an important anti-aging effect of N2N1. Indeed, pharmacologic and genetic manipulations that increase NAD+ levels has become a standard way to increase both chronological and replicative life spans (RLS) of cells, and is very favorable for stem cell self-renewal.29 Our original experimental data pointed to cytoplasmic NAD(P)H dehydrogenases NQO1, NADH-dependent cytochrome b5 dependent reductase (CYB5Rn) or NADPH cytochrome P450 reductase (POR) as a possible users of N2N1. The activities of all enzymes are measured using cytochrome c as the surrogate electron acceptor from NADH or NADPH.30 Both NQO131 and NADH-dependent cytochrome b5 reductase (CYB5R3) may use both NADH and NADPH and both appear to play active roles in aging.32 We showed that oxidative phosphorylation inhibitors did not affect the reaction and that dicumarol completely erased the effect of N2N1. We also showed that pHMB had no effect. These results allowed us to conclude that NQO1 is most likely to be the enzyme that is responsible for the N2N1 anti-aging effect. CYP enzymes could not be completely excluded from the candidate list because inhibition with dicumarol of NADPH : N2N1 : cytochrome c electron transfer was not complete (Fig. 5b).
NQO1 is a cytosolic flavoprotein-dependent enzyme that catalyzes two electron reductions of multiple substrates including quinones and vitamins K and E. NQO1 is ubiquitously expressed and can utilize NAD(P)H and some other reducing cofactors, like nicotinamide riboside.33 NQO1 responds to NAD(P)+/NAD(P)H balance as a redox dependent switch, promoting binding or dissociation with its target proteins: p53, p63, p73, HIF1α, centrosome localized Sirt2, and PGC1α.34 As a result of NQO1 elevated activity, an increase in NAD+ level was observed35 that could be beneficial for survival of replicatively or chronologically aged cells. NQO1 is considered among the most important enzymes during oxidative stress and aging due to its ability to fully reduce quinones, which pose electrophilic stress, complete reduction of semi-quinones and thus prevent oxidative damage or modify ROS-based signaling. Ubiquinol itself is a very potent scavenger of ROS of different origin and structure.36
The cytoplasmic extract prepared from the replicatively younger cells (33 PD) revealed more NQO1 activity (Fig. 6b and Table S7b) and slightly elevated protein expression compared to the extract prepared from the cells entering senescence crisis (55 PD) or non-proliferative young cells (33 PD, in monolyer). While there is a difference in NQO1 expression and activity between replicatively young and old cells, this variance may not be large enough to explain irreversible cell-cycle withdrawal in senescence cells. It is possible that proteins or small molecule co-factors downstream of NQO1 action are responsible for NQO1:N2N1-mediated anti-aging effects. As ROS play role both in signal transduction37 and as modifying agents,38 NQO1-dependent redox catalysts like N2N1 could be an effective anti-aging treatment by interfering with ROS-signaling. There is also a possibility that N2N1 anti-aging properties are due to NAD+ mediated increases in PARP activity.
NQO1 expression is under control of the transcription factor Nrf2, an important player in aging prevention and a master transcription factor of oxidative and electrophilic stress responses. Nrf2 is up-regulated in long-lived animal species.39 Pharmacological activation of Nrf2 pathway has been used to prevent age-related tissue dysfunctions.40
It has been demonstrated that a non-toxic level of NQO1-dependent redox catalyst could be an effective anti-aging treatment. β-lapachone is a NQO1 partner and its involvement in aging prevention has been well documented.41 In our pilot experiments (Table 1) we also demonstrated a possible anti-aging effect of β-lapachone and its derivative, dunnione. Another well-described redox catalyst,42 DNMA (N,N-dimethyl-4-nitrosoaniline), was inadvertently described as a potent anti-aging compound during animal treatment.43 As shown in Table 2 of that study, 82% of DNMA treated animals vs. 31% of controls were alive at day 600 (treatment stopped at day 420), and at day 700, 49% of treated and 0% of controls remained. The overall increase of lifespan in DNMA treated group could be 30–35% greater than that of control animals. In conclusion, we can predict that artificial redox mediators or catalysts with suitable chemical and biological properties may be good candidates for pharmacological extension of lifespan in diverse organisms.
Cells and tissue culture conditions
NHDF were obtained from Lonza (CC-251). Progeroid fibroblasts were purchased from the Coriell Institute for Medical Research, as were Bloom syndrome cells, (GM16891), and Werner syndrome cells (AG12798). All cells were cultured in αMEM, 10% FBS, 5 mM glutaMAX, supplemented with bFGF (StemCell technologies) and penicillin/streptomycin mix (100 U each). Stromal cells from freshly isolated normal bone marrow were isolated and propagated in MyeloCult medium, (StemCell technologies, H5100) supplemented with 1 μM of hydrocortisone. SKM-1, K562, KG-1, THP-1 cell lines were cultured in RPMI, 10% FBS, pen/strep. Growth factor dependent UT6 cells were maintained in RPMI, 10% FBS, pen/strep and erythropoietin.
Measurement of RLS
RLS was measured in PDs (population doublings) based on formula: PD = Log2 (Number of cellsout/Number of cellsinput). For the 25 cm2 flask, we used 10K or 30K cells per flask as an input. Cell count and viability was measured on Vi-Cell XR cell viability analyzer (Beckman Coulter).
HTS for identification of anti-aging drugs
The screen was performed at the Case Western Reserve University School of Medicine Small Molecule Drug Development Core facility on 10K “pre-aged” (precultured for 45–50 PD) NHDF. The collection of biologically active molecules was compiled from LOPAC library (Sigma) and Bioactive Compound Library (Selleck Chemicals). A total of 2684 mechanistically annotated compounds were used for the screening. A set of redox catalysts were added to the screen, including: VA, dimethyl-nitrosoaniline, diethyl-nitrosoaniline, 1-nitroso-2-naphthol, 2-nitroso-1-naphthol, CYPMPO, DMPO, methylene blue and coniferron (Sigma-Aldrich). Stock solutions were prepared in DMSO at 10 mM. For screening, 384-well assay plates were prepared with final drug concentrations of 5 μM using a Janus liquid handling platform (Perkin Elmer) equipped with 50 nL pin transfer tool (V&P Scientific). For concentration–response studies, lead compounds were retested at eight concentrations in two-fold dilutions. A final DMSO concentration of 0.1% was not exceeded in the screening assay and in hit validation. The negative controls contained the same percentage of vehicle/DMSO. In each screening plate two vehicle columns (32 wells) served as controls. In each titration plate, four vehicle columns (64 wells) served as controls.
Measurement of SAβG activity
SAβG activity was measured in a cell lysate after adding 50 μl of: citric acid-sodium phosphate buffer (40–60 mM, pH 6.0), 1 mM of X-gal (Gold biotechnology), 0.1 mM of nitro blue tetrazolum salt (NBT, Gold biotechnology) and 0.1% of Triton X100 (Sigma-Aldrich). After 1 h, an ATP detection solution (20 μl, Cell Titer-Glo, Promega) was added to the samples. The reagents were added by MultiFlo FX dispenser (Biotek). Sample SAβG activity was measured at 615 nm with simultaneous detection of luciferase activity as a readout of ATP using an Enspire plate reader (Perkin Elmer). Viability was calculated as a ratio of luminescence values for each compound to corresponding plate-average vehicle-only values after background subtraction. Screening data was analyzed using Pipeline Pilot (Biovia) software package. All readings were averaged and normalized on corresponding controls. The output was a ratio of SAβG activity divided by the level of ATP.
Approximately 1000 NHDF were seeded in 96-well plate (white, opaque, tissue culture treated, flat bottom, Corning) in tissue culture medium described above. After ~18–24 h, vehicle, N2N1 or VA were added at different concentrations. Cell viability was evaluated after ~96 h using Cell Titer-Glo (Promega) according to manufacturer protocol.
The SOS ChromoTest kit with S9 supplement (i.e., Ames assay with liver enzyme activation) was used to evaluate potential mutagenicity of tested compounds (EBPI).
Comet assay was performed according to published protocol with minor technical modifications.44 Briefly, treated and control NHDF were harvested and placed in 0.5–0.7% LMP agarose (at 37 °C, ThermoFisher Scientific) prepared in 1xPBS. Instead of frosted slides, to increase gel visibility and to provide a scaffold for very fragile agarose gels a simple procedure was designed. Gaskets made of filter paper (1 mm thick) were prepared with ~5 mm inside hole and 3–5 mm outside border. Gaskets were placed on a glass slide and filled with cell suspension in liquid agarose at 37 °C. Samples were placed at 4 °C until fully solidified. The resulted agarose gels can be handled with forceps and cannot be lost or damaged during lysis, electrophoresis or staining procedures. Lysing Solution: 2.5 M NaCl, 100 mM EDTA, 10 mM Tris-HCl, 0.5% Triton X100, Proteinase K ~50 μg/ml. Electrophoresis Buffer: 300 mM NaOH, 1 mM EDTA. Neutralization Buffer: 0.4 M Tris-HCl pH 7.5. Staining Solution: Ethidium Bromide ~5 µM prepared in neutralization buffer or 1×TBE.
Amplex red assay
The reactions were set in 50 mM Tris-HCl, pH 7.5, 100 mM KCl, 2 mM MgCl2, 1 mM NAD(P)H, 50 μM Amplex red, with or without cytoplasmic extract prepared from NHDF. Horseradish peroxidase and Amplex red reagent were purchased from ThermoFisher Scientific. Each test (e.g., control or an experimental drug) was run in 5 independent wells, in 384-well plates (Nunc, Clear Polystyrene Plates) sealed with adhesive PCR film (ThermoFisher Scientific). All reaction mixes were prepared on ice and dispensed into cold plate (18 μl, with automatic pipette Rainin, EDP3, 0.1–1.2 ml) before addition of drug candidates (2 μl, with multichannel automatic micro-dispenser, Rainin, EDP3, 1–10 μl) or H2O2. The excitation at 544nm and emission at 590 nm were used to detect the resorufin fluorescence on Synergy H1, Hybrid reader (BioTek).
Cells were washed with 1xPBS and frozen at −80 °C as a pellet. Cells were lysed on ice in RIPA buffer supplemented with protease inhibitor cocktail, set V (EMD Millipore). Protein concentration was measured with Pierce BCA protein assay. Equal amounts of protein were loaded onto 4–12% polyacrylamide gel (Bio-Rad Laboratories) and electrophoresed at constant power of 45 watts, for 40 min. Proteins were transferred from gels to PVDF membranes (Bio-Rad Laboratories) per manufacturer protocols. To intensify signals, PVDF membranes after protein transfer, were air dried at room temperature and then rehydrated with 100% methanol and 1×PBS with 0.05% Tween 20. Membranes were blocked for 20–30 min at room temperature with 5% non-fat milk prepared in 1×PBS, 0.05% Tween 20. Primary and secondary antibodies (Supplementary Materials) were prepared in 5% non-fat milk, 1×PBS, 0.05% Tween-20. Peroxidase activity was measured using HyGlo (Denville scientific) detected on a ChemDoc MP Imaging system (Bio-Rad).
GSH/GssG and NAD+/NADH
Glutathione measurement was measured with glutathione assay kit, Cayman chemical according to manufacturer recommendations. For NAD/NADH the protocol used was that found in the NAD/NADH quantitation kit (Biovision) used.
Mitochondrial respiration and glycolysis
Tests were performed using Seahorse 24-well plates, XF24 sensor cartridge and a XF24 Extracellular Flux Analyzer (Seahorse Biosciences). ~50K NHDF per well. Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were measured using the XF24 Analyzer and Assay Wizard software in replicates of 4. Drugs were added directly to the XF24 Extracellular Flux Analyzer (Seahorse Biosciences) or cells were pre-incubated with drugs for different amount of time as indicated in Fig. S2.
Telomere length assessment
Absolute telomere length was evaluated by quantitative PCR method according to the published protocol.45 Cells were harvested and washed with 1×PBS. DNA was isolated using DNeasy Blood and tissue kit (Qiagen). Primers were ordered from IDT Technologies with HPLC purification provided by the manufacturer. Cycling conditions for both telomere and 36B4 products were: 40× (95 °C, 15"; 64 °C, 60") → 4 °C.
Chronological life span
Animal experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals of the NIH, and conducted under an approved Institutional Animal Care and Use Committee protocol. CLS was evaluated in mice (C57BL/6, females) treated with vehicle (DMSO, 0.01%), N2N1 (100 μM) or VA (1 mM) in drinking water. Treatment started at the age of one month. Groups: Control, 15 animals; N2N1, 18 animals; VA, 10 animals. The daily water consumption is equal to ~3 ml. Average middle age mouse weight around 30 g would make 10 μM/kg or 1.7 mg/kg dose of N2N1 or 100 μM/kg or 17 mg/kg dose of VA.
C. elegans (wild type, N2) were obtained from Caenorhabditis Genetics Center (CGC), University of Minnesota. For CLS experiments approximately one hundred L4/young adult animals were transferred to NMG agar plates supplemented with FudR (100 μM), vehicle (DMSO, 0.01%), N2N1 (100 μM) or VA (1 mM) and kept at 25 °C. Viability was assessed every second day.
Detection of reduced cysteines
EZ-link maleimide-PEG2-Biotin (ThermoFisher Scientific) procedure was used according to manufacturer protocol with ~106 NHDF. Cells were lysed on ice with protease inhibitors in RIPA buffer, 200 μl. Fifty microliters of cell lysate were mixed with 500 μl of acetone and incubated at −80 °C, for 30 min. After centrifugation, at 4 °C, at maximum speed, samples were re-suspended in phosphate buffer (pH6.0) and incubated with 0.1 μM maleimide-Peg2-Biotin, on ice for 1 h, followed by precipitation of labelled proteins with 5 volumes of acetone. Protein concentration was measured using the BCA (bicinchoninic acid) assay. Equal amounts of protein were loaded onto 4–12% polyacrylamide gel lanes (Bio-Rad Laboratories), electrophoresed at constant power of 45 watts, for 40 min, and transferred to PVDF membranes (Bio-Rad Laboratories). As described above for Western Blots, membranes were completely dried in room temperature air, rehydrated, and blocked for 20–30 min at room temperature with 5% non-fat milk dissolved in 1×PBS with 0.05% Tween-20. To detect biotin labeled molecules, reagents A and B from Vectastain Elite ABC Kit, (Vector Laboratories) were diluted 1:1000 in 1xPBS with 0.05% Tween-20 and incubated with membranes for 1 h at room temperature.
For detection of sulfhydryl groups Elman’s reagent was used with ~106 NHDF, ~40PD. Sulfhydryl groups were detected using Elman’s reagent (DTNB, 5,5′-Dithiobis(2-nitrobenzoic acid, Sigma-Aldrich). Cells were lysed on ice with protease inhibitors in RIPA buffer, 200 μl. Fifty microliters of cell lysate was mixed with 500 μl of acetone and incubated at −80 °C, for 30 min. After centrifugation, at 4 °C, at maximum speed, pellets were re-suspended in phosphate buffer (pH7.0) and protein concentrations were measured using the BCA assay. Equal amounts of protein from each analyzed sample were mixed with DTNB (0.5 mM)-GuHCl and absorbance was measured at 412 nm (Synergy H1, Hybrid reader, BioTek).
Cytoplasmic extract preparation
Cell pellet (2–3 × 106 cells, ~35–50 μl) was re-suspended in 200 μl of ice-cold CE buffer (NaCl 10 mM, MgCl2 1.5 mM, Tris-HCl 10 mM, pH7.5) supplemented with protease inhibitors and incubated on ice for no more than 3 min. After that, cell suspension was centrifuged at 0.6 rcf, 4 °C, for 3 min. Supernatant was carefully transferred into a new, pre-chilled tube.
Each test (e.g., control, an experimental drug at concentration N μM etc.) was run in five independent wells, in 384-well plates (Nunc, Clear Polystyrene Plates) sealed with adhesive PCR film (ThermoFisher Scientific). All reaction mixes were prepared on ice and dispensed into cold plate. The reaction mix (18 μl) before addition of drug candidates or corresponding substrate (2 μl) was dispensed using automatic pipette (Rainin, EDP3, 0.1–1.2 ml) with dispensing function. Experimental drugs were added with multichannel automatic micro-dispenser (Rainin, EDP3, 1–10 μl). The internal well size of 3.45 × 3.45 mm with 20 μl reaction mix volume generates the path equal to 1.6 mm. The reaction rates were calculated based on the following formulas: Δ[NAD(P)H] = ΔAbsorbance340nm/(6220 M−1 cm−1 × 0.168 cm); Δ[cytochrome c] = ΔAbsorbance550nm/(21,100 M−1 cm−1 × 0.168 cm). All experiments were performed on Synergy H1, Hybrid reader (BioTek). The measurement of absorbance at corresponding wave-length was taken every minute, at 37 °C.
Assays for VA
The reactions were set in 100 mM potassium phosphate buffer, pH 7.0, 1 mM NAD(P)H with 0.5 mM GssG (oxidized glutathione) or 5 mM hydrogen peroxide. The oxidation of NAD(P)H was monitored as an absorbance decrease at 340 nm. The turbidity assay with 0.1 mM of insulin was run with change of absorbance measured at 650 nm, without vortexing.
Assays for N2N1
The reactions were set in 50 mM Tris-HCl, pH 7.5, 100 mM KCl, 2 mM MgCl2, 1 mM NAD(P)H, 0.1% Triton X100 and, 0.1 mM of cytochrome c or CoQ10 and, freshly prepared cytoplasmic extract. Triton X100 was added into reaction mix to fully inhibit mitochondrial Complex I activity.46 Cytochrome c 10 mM stock solution was prepared in water. To prepare CoQ10 10 mM stock solution, CoQ10 powder was dissolved in absolute ethanol-Triton X100 mixture (90–10%) and kept at 70 °C for 5 min. Corresponding inhibitors (dicumarol, 25 μM; pHMB, 50 μM; rotenone, 2 μM; antimycin a, 2 μM; KCN, 1 mM) were added where required. The reduction of cytochrome c was observed as an increase of absorbance at 550 nm along with oxidation of NAD(P)H monitored as an absorbance decrease at 340 nm. The reduction of CoQ10 into ubiquinol was evaluated based on oxidation of NAD(P)H (decrease in absorbance at 340 nm).
CRISPR/Cas9 knockout generation
The CRISPR/Cas9 knockout plasmid with an insert to inactivate NQO1 was manufactured by Santa Cruz Biotechnology and used according to manufacturer recommendations. Primary cells, like NHDF, grow well only as relatively “dense” populations. The use of cellular populations instead of cell clones shortens times needed to detect knockout phenotypes. To generate stably knocked out cells, 105 NHDF cells at ~37 PD were seeded into five 25 cm2 flasks. After two days, medium was changed to OPTI-MEM, 10% FBS (no antibiotics) and 10 μg of CRISPR/Cas9 plasmid was transfected into the cells using the manufacturer’s transfection reagent (Santa Cruz Biotechnology). Three days after transfection, cells were harvested from the culture flasks and sorted on a Sony SH2 800 cell sorter using a GFP expression marker. 5 GFP positive cells were collected in a single well of 96-well plate. Total 12 wells were filled with GFP positive cells. Cells were grown in αMEM, 10% FBS, bFGF, pen/strep and scaled up to at least 105 cells in 25 cm2 flasks. The overall procedure added up to 7–10 PD. Each GFP positive population was tested for NQO1 expression by western blot (Fig. S7c). The cell population with presumably stable NQO1 knockout was used to quickly evaluate replicative capacity, measured in PD/day. N2N1 was used as a positive control, as it always speeds up cell cycling during first days of treatment, though it cannot prevent senescence, as cells continue to slow down their cell cycle, even in the presence of N2N1.
All data are available from the authors on request.
Childs, B. G., Durik, M., Baker, D. J. & van Deursen, J. M. Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nat. Med. 21, 1424–1435 (2015).
Swim, H. E. & Parker, R. F. Culture characteristics of human fibroblasts propagated serially. Am. J. Hyg. 66, 235–243 (1957).
Hayflick, L. & Moorhead, P. S. The serial cultivation of human diploid cell strains. Exp. Cell Res. 25, 585–621 (1961).
Dimri, G. P. et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA 92, 9363–9367 (1995).
Greenberg, E. F. & Vatolin, S. Symbiotic Origin of Aging. Rejuvenation research 21, 225–231 (2018).
Coppe, J. P., Desprez, P. Y., Krtolica, A. & Campisi, J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev. Pathol.-Mech. 5, 99–118 (2010).
Longo, V. D. et al. Interventions to slow aging in humans: are we ready? Aging Cell 14, 497–510 (2015).
Kirkland, J. L. & Tchkonia, T. Clinical strategies and animal models for developing senolytic agents. Exp. Gerontol. 68, 19–25 (2015).
Jaskelioff, M. et al. Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. Nature 469, 102–U1700 (2011).
Sahin, E. et al. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 470, 359 (2011).
Li, J. et al. AGING A conserved NAD(+) binding pocket that regulates protein-protein interactions during aging. Science 355, 1312 (2017).
Johnson, S. C., Rabinovitch, P. S. & Kaeberlein, M. mTOR is a key modulator of ageing and age-related disease. Nature 493, 338–345 (2013).
Xiong, Z. M. et al. Anti-aging potentials of methylene blue for human skin longevity. Sci. Rep. 7, 2475 (2017).
Lerner, C. et al. Reduced mammalian target of rapamycin activity facilitates mitochondrial retrograde signaling and increases life span in normal human fibroblasts. Aging Cell 12, 966–977 (2013).
Jones, D. P. Redox theory of aging. Redox Biol. 5, 71–79 (2015).
Leskovac, V., Svircevic, J., Trivic, S., Popovic, M. & Radulovic, M. Reduction of aryl-nitroso compounds by pyridine and flavin coenzymes. Int. J. Biochem. 21, 825–834 (1989).
Bisogno, F. R., Lopez-Vidal, M. G. & de Gonzalo, G. Organocatalysis and biocatalysis hand in hand: combining catalysts in one-pot procedures. Adv. Synth. Catal. 359, 2026–2049 (2017).
Yoo, E. H. & Lee, S. Y. Glucose biosensors: an overview of use in clinical practice. Sensors 10, 4558–4576 (2010).
Atamna, H. et al. Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. Faseb J. 22, 703–712 (2008).
Edamatsu, R., Mori, A. & Packer, L. The spin-trap N-tert-alpha-phenyl-butylnitrone prolongs the life-span of the senescence-accelerated mouse. Biochem. Biophys. Res. Commun. 211, 847–849 (1995).
Saito, K., Yoshioka, H. & Cutler, R. G. A spin trap, N-tert-butyl-alpha-phenylnitrone extends the life span of mice. Biosci. Biotech. Bioch 62, 792–794 (1998).
Thulabandu, V., Chen, D. & Atit, R. P. Dermal fibroblast in cutaneous development and healing. Wiley interdisciplinary reviews. Develop. Biol. 7, e307 (2018).
Bara, J. J., Richards, R. G., Alini, M. & Stoddart, M. J. Concise review: bone marrow-derived mesenchymal stem cells change phenotype following in vitro culture: implications for basic research and the clinic. Stem Cells 32, 1713–1723 (2014).
Burbello, A. T., Baskovich, G. A., Dobrokhotova, E. G. & Slesarev, V. I. Protective effect of antioxidants in methemoglobinemia caused by sodium nitrite in experimental studies. Gigiena truda i professionalanye zabolevaniia 8, 13–15 (1991).
Burbello, A. T., Vishvtseva, V. V., Denisenko, P. P., Safonova, A. F. & Dobrokhotova, E. G. The limitation of glucose catabolism as a factor in protection during hypoxia. Eksp.'naia i Klin. Farmakol. 58, 49–52 (1995).
Ivanova, G. & Enchev, V. Does tautomeric equilibrium exist in ortho-nitrosonaphthols? Chem. Phys. 264, 235–244 (2001).
Krzan, A. & Mavri, J. Nitroso-naphthol quinone-monooxime tautomeric equilibrium revisited: evidence for oximo group isomerization. Chem. Phys. 277, 71–76 (2002).
Zaware, S. B., Gonnade, R. G., Srinivas, D., Khan, A. & Rane, S. Y. Antioxidant and anticancer activities of supramolecularly controlled magnetostructural halo-oximes of lawsone. New J. Chem. 35, 1615–1623 (2011).
Rimmele, P. et al. Aging-like phenotype and defective lineage specification in SIRT1-deleted hematopoietic stem and progenitor cells. Stem Cell Rep. 3, 44–59 (2014).
Guengerich, F. P., Martin, M. V., Sohl, C. D. & Cheng, Q. Measurement of cytochrome P450 and NADPH-cytochrome P450 reductase. Nat. Protoc. 4, 1245–1251 (2009).
Navas, P., Villalba, J. M. & de Cabo, R. Importance of plasma membrane coenzyme Q in aging and stress responses. Mitochondrion 7, S34–S40 (2007).
de Cabo, R., Siendones, E., Minor, R. & Navas, P. CYB5R3: a key player in aerobic metabolism and aging? Aging-Us 2, 63–68 (2010).
Friedlos, F., Jarman, M., Davies, L. C., Boland, M. P. & Knox, R. J. Identification of novel reduced pyridinium derivatives as synthetic co-factors for the enzyme DT diaphorase (NAD(P)H dehydrogenase (quinone), EC 22.214.171.124). Biochem. Pharmacol. 44, 25–31 (1992).
Siegel, D. et al. Redox modulation of NQO1. PLoS ONE 13, e0190717 (2018).
Gaikwad, A., Long, D. J. 2nd, Stringer, J. L. & Jaiswal, A. K. In vivo role of NAD(P)H:quinone oxidoreductase 1 (NQO1) in the regulation of intracellular redox state and accumulation of abdominal adipose tissue. J. Biol. Chem. 276, 22559–22564 (2001).
Ross, D. & Siegel, D. Functions of NQO1 in cellular protection and CoQ(10) metabolism and its potential role as a redox sensitive molecular switch. Front. Physiol. 8, 595 (2017).
Hekimi, S., Wang, Y. & Noe, A. Mitochondrial ROS and the effectors of the intrinsic apoptotic pathway in aging cells: the discerning killers. Front. Genet. 7, 161 (2016).
Reczek, C. R. & Chandel, N. S. ROS-dependent signal transduction. Curr. Opin. Cell Biol. 33, 8–13 (2015).
Lewis, K. N. et al. Regulation of Nrf2 signaling and longevity in naturally long-lived rodents. Proc. Natl. Acad. Sci. USA 112, 3722–3727 (2015).
Liu, X. F. et al. Nrf2 as a target for prevention of age-related and diabetic cataracts by against oxidative stress. Aging Cell 16, 934–942 (2017).
Lee, J. S. et al. Beta-lapachone, a modulator of NAD metabolism, prevents health declines in aged mice. PLoS One 7, e47122 (2012).
Hones, J., Muller, P. & Surridge, N. The technology behind glucose meters: Test strips. Diabetes Technol. The. 10, S10–S26 (2008).
Goodall, C. M. & Lijinsky, W. Oncogenicity tests of p-nitroso-N,N-dimethylaniline and p-nitroso-N,N-diethylaniline in NZR rats and NZO mice. Pathology 8, 143–149 (1976).
Vatolin, S. Y. et al. Scheduled perturbation in DNA during in vitro differentiation of mouse embryo-derived cells. Mol. Reprod. Dev. 47, 1–10 (1997).
O'Callaghan, N. J. & Fenech, M. A quantitative PCR method for measuring absolute telomere length. Biol. Proced. Online 13, 3 (2011).
Ushakova, A. V., Grivennikova, V. G., Ohnishi, T. & Vinogradov, A. D. Triton X-100 as a specific inhibitor of the mammalian NADH-ubiquinone oxidoreductase (Complex I). Biochim. Biophys. Acta 1409, 143–153 (1999).
This study was supported by NIH grant R35HL135795 to J.P.M. and by Aplastic Anemia and MDS International Foundation research award AAMDS1706JM given to S.V.
S.V. and J.P.M. have ownership interests and filed a patent application for structural modification of VA and N2N1 and their application as anti-aging drugs. All other authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Vatolin, S., Radivoyevitch, T. & Maciejewski, J.P. New drugs for pharmacological extension of replicative life span in normal and progeroid cells. npj Aging Mech Dis 5, 2 (2019). https://doi.org/10.1038/s41514-018-0032-4
This article is cited by
The quest to slow ageing through drug discovery
Nature Reviews Drug Discovery (2020)